Buildout and integration of an automated high-throughput CLIA laboratory for SARS-CoV-2 testing on a large urban campus

Lena Landaverde1,2,3, David McIntyre2,4,5, James Robson2, Dany Fu4,6,7, Luis Ortiz2,4,5, Rita Chen1,8, Samuel M.D. Oliveira4,8, Andy Fan2, Amy Barrett9, Stephen P. Burgay10, Stephen Choate11, David Corbett12, Lynn Doucette-Stamm3, Kevin Gonzales13,14, Davidson H. Hamer1,15,16,17, Lilly Huang18, Shari Huval11, Christopher Knight11, Carrie Landa19, Diane Lindquist20, Kelly Lockard21, Trevor L. Macdowall11, Elizabeth Mauro11, Colleen McGinty22, Candice Miller1, Maura Monahan11, Randall Moore23, Judy Platt19, Lloyd Rolles19, Jeffrey Roy23, Tracey Schroeder11, Dean R. Tolan3,24, Ann Zaia25, Robert A. Brown26,27, Gloria Waters14,28, Douglas Densmore4,5,8, Catherine M. Klapperich1,2,3,*

1 Precision Diagnostics Center, Boston University, Boston, MA
2 Biomedical Engineering, College of Engineering, Boston University, Boston, MA
3 Boston University Clinical Testing Laboratory, Boston University, Boston, MA
4 Design, Automation, Manufacturing, and Prototyping Laboratory, Boston University, Boston, MA
5 Biological Design Center, Boston University, Boston, MA
6 Software & Application Innovation Lab, Hariri Institute for Computing, Boston University, Boston, MA
7 Department of Biology, Boston University, Boston, MA
8 Electrical and Computer Engineering, Boston University, Boston, MA
9 Office of the Provost, Boston University, Boston, MA
10 Office of External Affairs, Boston University, Boston, MA
11 Information Services & Technology, Boston University, Boston, MA
12 Health Information Privacy Resources, Boston University, Boston, MA
13 BU Healthway, Boston University, Boston, MA
14 Office of Research, Boston University, Boston, MA
15 Department of Global Health, Boston University School of Public Health, Boston University, Boston, MA
16 Section of Infectious Disease, Department of Medicine, Boston University School of Medicine, Boston, MA
17 National Emerging Infectious Disease Laboratory, Boston, MA
18 Office of General Counsel, Boston University, Boston, MA
19 Student Health Services, Healthway, Boston University School of Public Health, Boston, MA
20 Health Privacy and Compliance, Boston University, Boston, MA
21 Continuous Improvement & Data Analytics, Boston University, Boston, MA
22 Operations, Boston University, Boston, MA
23 Sourcing and Procurement, Boston University, Boston, MA
24 HFI Laboratory, Boston University, Boston, MA
25 Occupational Health Center, Boston University, Boston, MA
26 College of Engineering, Boston University, Boston, MA
27 Office of the President, Boston University, Boston, MA
28 College of Health and Rehabilitation Services, Sargent College, Boston University, Boston, MA

ABSTRACT

In 2019, the first cases of SARS-CoV-2 were detected in Wuhan, China, and by early 2020 the first cases were identified in the United States. SARS-CoV-2 infections increased in the US causing many states to implement stay-at-home orders and additional safety precautions to mitigate potential outbreaks. As policies changed throughout the pandemic and restrictions lifted, there was an increase in demand for COVID-19 testing which was costly, difficult to obtain, or had long turn-around times. Some academic institutions, including Boston University (BU), created an on-campus COVID-19 screening protocol as part of a plan for the safe return of students, faculty, and staff to campus with the option for in-person classes. At BU, we put together an automated high-throughput clinical testing laboratory with the capacity to run 45,000 individual tests weekly by Fall of 2020, with a purpose-built clinical testing laboratory, a multiplexed reverse transcription PCR (RT-qPCR) test, robotic instrumentation, and trained staff. There were many challenges including supply chain issues for personal protective equipment and testing materials in addition to equipment that were in high demand. The BU Clinical Testing Laboratory (CTL) was operational at the start of Fall 2020 and performed over 1 million SARS-CoV-2 PCR tests during the 2020-2021 academic year.

https://doi.org/10.1016/j.slast.2022.06.003

Received 31 January 2022; Received in revised form 2 May 2022; Accepted 12 June 2022

2472-6303/© 2022 The Author(s). Published by Elsevier Inc. on behalf of Society for Laboratory Automation and Screening. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Introduction

Impact of COVID-19 in Boston and Boston University

In late 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus, was first reported in Wuhan, China [1–3]. Cases in the United States were documented in Washington State on January 20, 2020, and shortly after the World Health Organization (WHO) declared the Coronavirus disease 2019 (COVID-19) pandemic in March of 2020 [4,5]. At the height of the SARS-CoV-2 pandemic, individuals of all occupations were taking additional precautions during stay-at-home orders to ensure public safety and health. As the demand for testing increased in parallel with state restrictions lifting and increasing cases in the US, COVID-19 screening was either unavailable, costly, or had test-to-result times that were too long to work as an effective screening tool [6]. As part of the initial shutdowns in March 2020, Boston University (BU) pivoted to remote learning and finished the remainder of the semester with online course work. At that time, we began to plan for the return of students in August 2020 which included the construction of a new high-throughput testing laboratory to maintain a testing cadence and turnaround time sufficient to minimize viral spread on campus [7].

For BU, SARS-CoV-2 screening testing was part of a multi-faceted strategy to permit the return to a residential campus and in person teaching in the Fall of 2020. There were examples of newly formed testing facilities with the same purpose, one of the first and most notable was a team at University of California Berkeley that provided a detailed blueprint for converting the Innovative Genomics Institute to test for SARS-CoV-2 at the university and in the local community [8]. In Europe, the Francis Crick Institute developed the Crick COVID-19 Consortium with publicly available standard operating procedures (SOP) [9] for other organizations to follow. At Boston Medical Center, the Center for Regenerative Medicine extended the capacity of the BMC Department of Pathology and Laboratory Medicine to perform real-time reverse transcription polymerase chain reaction (RT-qPCR) COVID-19 testing with a 24-hour turn-around time [10,11]. These successes led us to explore doing the same for our entire campus, including 45,000 faculty, students, and staff [12]. A team was quickly assembled to stand up an on-site high-throughput clinical laboratory from the ground up. The goal was to enable faculty, staff, and students to safely return with an option for in-person or remote classes, a program known as BU’s Learn from Anywhere [7] during the 2020-2021 academic year. Across the US, many institutions were making similar plans and it is also important to credit the plethora of online collaboration and communication platforms like Slack where scientists from academic, government, and industry came together to assist each other in these endeavors.

By Fall of 2020, BU implemented a multi-stage plan to perform screening testing of approximately 45,000 students, faculty, and staff for COVID-19. The BU campus comprises three locations in Boston and Brookline, MA. The largest location is the Charles River Campus (CRC), which is approximately three miles from the next largest Boston University Medical Campus, followed by the smaller, Fenway Campus. The proposed plan included an on-site testing facility, collection sites, and contact tracing [7]. Instrumental to the plan was building a clinical testing facility with the capacity to test students, staff, and faculty weekly. The development of the Boston University Clinical Testing Laboratory (BU CTL) was a collaborative effort between the BU Office of Research, the Precision Diagnostics Center (PDC), and the Design, Automation, Manufacturing, and Prototyping (DAMP) Laboratory. Specifically, the development and implementation of the facility required a combination of automation, assay development and systems engineering and management. In addition, the new BU CTL would have to meet regulatory and legal requirements set forth under the Clinical Laboratory Improve-
ments Amendments (CLIA) and Massachusetts state law as well as apply for a Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for a laboratory developed test for COVID-19 [13].

Major decision points

The BU CTL stands out as a technically advanced, purpose built, high throughputs automated testing facility. We implemented a high sensitivity RT-qPCR test, integrated automation to support the required throughput, and developed a customized Laboratory Information Management System (LIMS) infrastructure. The sample preparation and RT-qPCR assay were developed to meet both EUA [14] and CLIA [15,16] requirements which are detailed in publicly available documentation (Fig. 1).

After reviewing various predictive models of SARS-CoV-2 transmission on campus, BU decided to test undergraduate students twice a week and all others based on an assigned testing category with routine asymptomatic screening testing [7]. This resulted in a projected test load of 5,000 tests/day with a required next day turnaround time. Building the physical and digital infrastructure required a university-wide team to source materials, equipment, and human resources to plan and build the space. The team comprised of Sourcing and Procurement, Office of Research, Legal, Medical Advisory Board, Marketing and Communications, is shown in Fig. 2a. The project was driven by the following design requirements: adequate laboratory space, safe and approved sample collection and transportation, efficient RNA purification, assay development, automation, sample lineage tracking, CLIA, EUA, and staffing. An ongoing challenge was equipment, material, and personal protective equipment (PPE) supply chain issues caused by the global pandemic [17]. Availability of resources and equipment was a major driving factor in the decisions (Fig. 1) made to build the high throughput clinical laboratory.

Materials and methods

Identifying a space for CTL for high throughputs automated testing

Identifying a dedicated space on BU’s CRC was critical. It needed to house sample receiving, automation robots, qPCR machines, and all auxiliary equipment with the appropriate laboratory footprint. A laboratory space was identified within the Rajen Kilachand Center for Integrated Life Sciences & Engineering. The space was initially designed to house yet to be purchased automation equipment for the Design Automation Manufacturing Prototyping Laboratory, so many of the basic infrastructure needs were in place.

Although the space had some of the required infrastructure, additional renovations were necessary to convert the space into a clinical testing laboratory. The CTL layout required separated stations to mitigate contamination, maintain order, and follow the streamlined workflow illustrated in Fig. 2b. Samples follow a defined workflow upon arrival in the CTL to maintain sample lineage and tracking with each station defined by the process performed. Electrical work included installing additional emergency power outlets to support critical instrumentation, refrigeration, and freezer units. Additional ceiling support was added for uninterrupted power supplies as backup for the critical robotics and qPCR machines. The space was physically modified with doors to include separated entrances for gowning and to close off the initially open, shared space; all doors were secured by key or swipe access only. This included an additional adjacent space incorporated to house refrigeration, freezers, and the maintain small existing CLIA testing facility. Images of the equipment and space (Supplemental Figures).

* Corresponding author: 44 Cummington Mall, Boston, MA 02215
E-mail address: catherin@bu.edu (C.M. Klapperich).
Fig. 1. The multi-staged approach for building the Boston University Clinical Testing Laboratory. Each branch builds upon strategic decisions made with the best available information at the time and critical to the function of the laboratory. Each branch breaks down different categories to demonstrate how each connect to the physical laboratory. Included here are also considerations made that are tangential to the build out of the automated testing process. The laboratory was built to meet both Emergency Use Authorization (EUA) and Clinical Laboratory Improvements Amendments (CLIA) requirements.

On campus sample collection sites

Anterior nares (lower nostril) samples were self-collected under observation. BU set up five sample collection sites: four on the CRC campus and one on the Boston University Medical Campus. Remote observed collections are also performed for individuals in campus quarantine [7]. All students, faculty and staff were required to complete a daily symptom attestation before coming to campus. Asymptomatic individuals received an electronic clearance badge that they had to present upon entering the collection site. After check-in, individuals would sanitize their hands and approach a check-in station. Everyone was handed a sample tube with a unique barcode and directed to a swabbing station. The observer provides the swab at the swabbing station. Observed swabbing occurs in large, windowed cubicles to allow for social distancing and a physical barrier while the individual removed their mask to swab. A time study showed that the entire process of arriving at the site, checking in, and swabbing required less than 5 minutes for almost all users.

All sample collection sites had windowed check-in and self-collection booths, clear labeled signs, directional arrows on the floor spaced for social distancing, and sanitizer dispensers available between stations. To ensure a clean, sterile surface between collections, a sealed single swab was placed on top of a sheet of parchment. During sample collection the tube cap was placed upside down on the parchment paper while the uncapped tube was placed in a small metal cup to hold the sample tube and prevent spilling. The parchment paper, swab wrapper, and broken off end of swab were disposed of in trash receptacles. A Health Insurance Portability and Accountability Act (HIPAA), Hazardous Material Regulations, and Occupational Safety and Health Administration certified courier transferred samples on a scheduled basis to the CTL. To ensure the safe transport of the samples and compliance with biosafety requirements samples were packaged in Test n’ Toss Disposable Test Tube Racks (Whitney Medical Solutions, Niles, IL) that were contained in a sealed bag. The sealed containers were transported in customized corrugated cardboard boxes labeled with biohazard information, return address, and delivery address.

Idea
tion and development of assay and sample testing process flow

In early 2020, the gold standard testing strategy recommended by the Center for Disease Control and Prevention (CDC) was testing the nucleocapsid (N) gene in 3 target regions as a singleplex RT-qPCR [6,18]. The CDC introduced the first EUA primer and probe set [19]. At the time the CTL was establishing an assay protocol, two targets (N1 and N2 with RNase P (RP) as the human material control) were required to identify positive cases. There were also limited multiplex RT-qPCR options with EUAs for clinical use. An example of a widely available option was the TaqPath COVID-19 combo kit [20] (Thermo Fisher, Waltham, MA) that targeted the S (spike), ORF1ab, N regions and included a spiked in internal control ms2phage. However, the kit at the time did not contain a human specific control and was costly even at scale for our application [20].

We designed a RT-qPCR test (LDT) and submitted it for FDA EUA in July of 2020. The BU SARS-CoV-2 Test uses primer and probe sets (IDT Custom, Coralville, Iowa) targeting the N1 (FAM-Tagged) and N2 (YAK-Tagged) SARS-CoV-2 genetic sequences and one human cellular material control (RNase P (Cy5-Tagged)) in each well. Overall performance of the assay automation workflow required incorporation of external run controls on each plate, including a positive template control (2019-nCov, nucleocapsid gene), a negative extraction control (NEC) and a no template control (NTC). The assay uses the CDC EUA kit sequences for
Fig. 2. a. BU’s CTL buildout was a multi-departmental effort within the university and a collaboration of both the Charles River Campus and Boston University Medical Campus. The groups involved were integral to developing many of the important campus support of COVID-19 screening testing including contact tracing and housing. b. The CTL workspace was divided into sections based on the tasks performed in each section: Sample Accessioning, Sample Aliquoting, RNA Extraction, qPCR Preparation, and RT-qPCR. Specific considerations were made to minimize cross contamination and to isolate the qPCR preparation station away from other processes. Each laboratory staff member would gown and wear appropriate personal protective equipment upon entry. Also included in the diagram is the dedicated cold storage spaces for reagents and samples. Images of the laboratory space are available in the Supplemental Data.

the BU-SARS-CoV-2 Test in a multiplexed assay [18]. The costs for the 2020-2021 academic year averaged $12.70 per test.

Biosafety and personal protective equipment

A biosafety SOP was developed following CDC guidelines in collaboration with BU Environmental Health and Safety. All samples arriving to the laboratory are counted and inventoried by technicians without opening packaging and placed into a 4°C fridge until further processing. The first processing step is to heat inactivate samples in a dry bead bath under a biosafety hood. All specimens remain closed until after this step. Lab staff wear new surgical face masks, disposable lab coats, and gloves while in the laboratory. When handling active samples, individuals are required to wear an additional back tying disposable lab gown, face shield and booties. Samples follow a unidirectional flow to maintain sample lineage and minimize any chance of cross contamination (Fig. 2b).

High-throughput automation concept and system design

Hamilton Microlab STAR Robotic Systems

The BU CTL is outfitted with seven configured Hamilton Microlab STAR (Hamilton Robotics Company, Reno, NV) automated liquid handling systems. The instruments run protocols written in Hamilton’s VENUS software with programmable hardware and integrated data handling. The configurability of the Microlab STAR is unique from other all-inclusive or single purpose systems which include instruments such as KingFisher (ThermoFisher, Waltham, MA), QIAsymphony (Qiagen,
Hilden, Germany), or MANTIS (Formulatrix, Bedford, MA). The MicroLab STAR can be modified to execute multiple tasks due to its flexible deck layout and modular components that lends to developing unique integrated automation protocols. Additionally, the instruments can be adapted to various assay and sample preparation protocols when large-scale COVID-19 testing is no longer needed.

Hamilton’s direct from manufacture consumables, equipment, and parts were integral to ensure receipt and installation on schedule for the July 2020 piloting of testing. We considered other systems but ran into supply chain issues for instruments and consumables as the US rapidly began to scale up testing in mid-2020. For example, the ThermoFisher KingFisher (ThermoFisher, Waltham, MA) instrument was listed as authorized equipment on several EUAs including the ThermoFisher TaqPath EUA, drastically reducing their availability. Lastly, the support provided by the engineers from Hamilton was integral to getting the systems set up and processing samples in 12 weeks. Automation methods were first validated in the laboratory with water, reagents, and utilizing well characterized discarded samples from other CLIA testing laboratories.

The sample processing throughput was mapped for the planned 5000 tests per day over a 7-day period by estimating the total run times on instruments including reagent preparation and manual labor (Fig. 3a). The calculation and estimates were a combination of times for manual labor and automation instrumentation time. Reagent preparation and loading time is accounted for between instrument runs. The final calculation accounting for manual processes is a total of 6200 tests processed per day with next-day results. The entire automation process includes 7 MicroLab STAR systems: 1 for sample aliquoting, 3 for RNA purification and extraction, and 3 for qPCR Preparation (Fig. 3a).

The following sections have integrated descriptions of both manual and automated steps highlighting the advantages and limitations of robotic automation. The combined descriptions also reinforce the critical importance of an organized and systematic workflow that considers both manual and automated steps performed or managed by clinical staff.

**Compatibility of anterior nares swabs and collection vials for automation**

Nasopharyngeal (NP) swabs were the gold standard collection method for COVID-19 testing using RT-qPCR at the time of establishment of the CTL. These tests were typically performed within a hospital or clinic using a process similar to influenza sample collection. However, as the need for SARS-CoV-2 testing increased, there was a worldwide shortage of NP swabs and viral transport media used in collection tubes. Detailed investigations were made into alternative sample types, this included saliva, buccal, and anterior nares (AN) collections.

Although each sample collection type had its advantages, the AN swab met multiple requirements. Because they are less complicated to make, AN swabs were more widely available and by late spring of 2020 had been previously EUA approved as a sample type collection type for COVID-19 [21]. An additional advantage of AN swabs is that they can be used for self-collection, especially with a non-hazardous buffer such as Phosphate Buffer Solution (PBS) or saline. At the time of assay development, there was minimal information and documentation on the success of saliva sample types for large scale asymptomatic clinical testing. There were known issues with sample viscosity and automation instrumentation, so we selected the AN swab.

Due to the high demand of materials, intensive research was performed on identifying compatible sample collection kits. BU sourced collection kits from Puritan Medical Products (Guilford, ME) and in conjunction with collection kits from other vendors. The finalized selection of collection materials was determined by rigorous testing and comparison of collection tube and swab parameters. Tube size, barcode type, barcode placement, and sample volume were critical for automation compatibility. All sample collection tubes are loaded onto either 24 or 32-tube sample carriers (Hamilton Robotics Company, Reno, NV) which can carry either 14.5-18 mm or 11-14 mm outer diameter tubes, respectively. Sample barcodes are read through a window on the sample carriers by the Autoload (Hamilton Robotics Company, Reno, NV) and must meet instrument specifications (ML STAR Autoload Specifications). During aspiration steps, it was essential that the robot tips could...
reach the surface of the sample liquid and reach a minimum depth in the tube to account for volume displacement. Customized 3D printed risers (uPrint SE, Stratasys, Eden Prairie, MN) were also developed to ensure each individual tube was at the correct height. Lastly, multiple AN swab options were tested for swab quality (minimal shedding of material) and swab breakpoints (location the swab would be broken in the tube). Swab breakpoints determined if the swab would be compatible with the height of the tube while also being easily removed by staff before the initial aspiration step. Our vials included a combined swab and cap or a patented cap that allows for a swift uncapping and swab removal in one action.

**Manual Inactivation, accessioning, and automated sample aliquoting**

Samples arrive at the laboratory and are first processed manually for inactivation and sample accessioning. The laboratory processes each sample by disinfecting the tubes with 70% ethanol and inactivating samples at 95°C for 10 min. inside a biosafety cabinet. Once inactivated, samples are scanned into the LIMS system and marked as received before being uncapped and loaded onto carriers for the Sample Aliquot Hamilton Microlab STAR. The Sample Aliquot Microlab STAR is a 16-channel system that consists of tip carriers, sample carriers, plate carriers, tube carriers, and an autoload that aspirates and dispenses samples into 96-well deep-well plates for nucleic acid extraction (Fig. 4).

**Automated magnetic bead-based RNA extraction**

Automated isolation of nucleic acids from crude sample material was achieved using the MagMAX™ Viral/Pathogen II (MVP II) Nucleic Acid Isolation Kit (ThermoFisher, Waltham, MA). The extraction kits include magnetic beads with a silica coated surface and a magnetic core. Nucleic acids are absorbed to the silica-surface of the beads in the presence of isopropanol and high concentrations of chaotropic salts, which remove water from hydrated molecules in solution. Once bound to the magnetic beads, the nucleic acids can be separated from the solution with a magnet. Polysaccharides and proteins do not adsorb to the beads and are removed by subsequent washing. Pure nucleic acids are then eluted from the beads by applying low-salt conditions and heat (Fig. 3b). The MagMAX™ Kit’s manual protocol [22] was modified and scaled to be compatible with our automation. These changes included an additional ethanol wash step, dead volumes, and reusing waste aspiration tips. At the time of development, there was no published Hamilton Method for the MagMAX™ Kit that accounted for tip reuse, maximizing the deck layout, and integrated with sample data capturing.

The three RNA Extraction Hamilton Microlab STAR instruments’ deck layouts include tips carriers, tip isolators, reagent carriers, Hamilton Heater Shaker (Hamilton Robotics Company, Reno, NV), and Magnum FLX magnetic ring stand (Alpaqua, Beverly, MA). The system can process a maximum of 4 plates in a single run and takes approximately 2.5 hours. The plate map information from the Sample Aliquot step is mapped to the final elution plates when the RNA Extraction method is complete.

Challenges resulted from unique liquid properties and an effort to reduce tip waste in the protocol. Initial validation with reagents and discarded samples exposed contamination issues from droplets generated during liquid waste disposal in the Hamilton MFX Gravity Waste Module, unwanted liquid retention in tips, and the formation of bubbles post-reagent dispense. The method was tested between liquid class modifications by implementing a checkered Extraction Plate layout with alternating nuclease free water and positive control samples to look for and eliminate cross well contamination. Changing dispense and aspiration speeds within the liquid classes module resolved contamination issues.
High-throughput qPCR preparation for 384-well plates

To maximize the test throughput and minimize turnaround time, we consolidated 4 elution plates from the extraction robots into one 384-well plate for qPCR (Fig. 4). Consolidation is performed by the qPCR Prep Hamilton Microlab STAR instruments. There are 372 purified RNA samples per plate and 9 control wells. Lab Technologists prepare reaction mixtures that contain the Applied Biosystems TaqPath Master no ROX Master Mix (ThermoFisher, Waltham, MA), Nuclease Free Water, and iDT Primer and Probe Mix (iDT Custom) (Integrated DNA Technologies, Coralville, IA). The three controls are transferred to the qPCR plate during the PCR set up steps. Each 384 well qPCR plate will contain 1 Positive qPCR Addition Control, 4 NECs and 4 NTCS. A human cellular material control, RNase P (RP), is expected to be present in all valid samples and the NEC. RNase P acts as both an extraction control and an internal control.

The qPCR Prep Hamilton Microlab STAR is used to set up the RT-qPCR reactions. It has the shortest run time of all robots in the process and uses the CO-RE 96-probe Head to quickly aspirate the reaction mix from a deep well midi plate into the 384-well plate followed by addition of the purified RNA samples with mixing. The challenge with this step is the liquid handling for the viscous reaction mix, which can lead to failed RT-qPCR runs. Specific to automation, optimization programming settings for liquid classes for the reaction mix were made by adding a mix step prior to aspirating with no following and no blow out. The positive qPCR control is added manually by the CTL staff after the plate is filled. The plate is then manually sealed and loaded onto the QuantiStudio 7 Flex. Output files are created by the qPCR Prep Hamilton Star which are formatted for the QuantiStudio 7 Flex. Data from the run is analyzed on the Design and Analysis 2 (Applied Biosystems, Waltham, MA) software and results are confirmed by a technologist and the Clinical Lab Supervisor.

Quality control, process scheduling, and SOPs

The BU CTL has quality control steps integrated into all of the SOPs. Each section highlighted in Fig. 2b has daily checklists that include calibration of instruments, cleaning of each station, inventory maintenance, and waste removal. Steps that require manual manipulations like sample accessioning and manual decapping have a minimum of 2 technicians checking to confirm that each step is performed accurately. The laboratory maintains the workflow using key organizational tools including color coded racks, labeled samples and plates, active communication, process specific stations and biosafety hoods, and labeled sample storage boxes. Every sample is documented at each step in the LIMS system further detailed in the section “Clinical laboratory data and integration of LIMS.” All laboratory protocols are reviewed during CLIA surveys at which the CTL has been found to have no deficiencies in any of the workflows or processes.

In addition to the above processes, the laboratory’s unique workflow and coordinated processing is driven largely by active communication between technologists, lab managers, and the supervisor (Fig. 4). The lab uses Microsoft Teams (Microsoft, Seattle, WA) with designated channels for each working shift, capturing sample issues and automation errors. This approach minimizes delays in response, actively provides updates for all individuals, and quickly resolves any issues. The lab has a universal shared Excel (Microsoft, Seattle, WA) tracking sheet that captures when samples are loaded onto an instrument and estimates completion times. This provides a live activity tracker for the clinical staff who manually transfer completed plates or samples to the next station.

It is important to note that this is a duplicate system and not a part of the LIMS workflow.

Clinical laboratory data and integration of LIMS

Tracking data and sample lineage is critical to the management of the information produced in the laboratory. The CTL implemented a LIMS that receives orders from the electric medical record (EMR) systems, receives data captured from automation instruments, manages sample lineage, tracking, and conducts reporting back to the EMR systems (Fig. 5).

The laboratory uses eLabNext (Cambridge, MA) a commercially available web-based LIMS that has robust APIs that receives both data from the laboratory and EMRs. To fully integrate the LIMS to our clinical workflow, we developed custom features with eLabNext to allow for seamless secure data transfer and increase laboratory efficiency. An example of a step captured by the LIMS system occurs during accessioning, where each individual sample is updated in the LIMS system to indicate that it has been received in the laboratory. The seamless and paperless capture of all information optimizes the workflow while maintaining data integrity and security. We depend on secure APIs for data transfer between the automation instrumentation and LIMS. To support the EMR reporting and test ordering, Health Level Seven (HL7) integrations were developed with the two independent EMR systems for faculty and staff, and students.

To summarize a data workflow, each automation instrument takes in a data file and creates output files associated with barcoded plates and samples. These are tracked throughout the process up until results are exported from the completed qPCR plates. Each sample has a tracking lineage that includes lot numbers, sample process, plate information, and results. All results are checked by the Clinical Laboratory Supervisor prior to submission to the EMRs. All steps have duplicate manual checks to confirm results and sample integrity. Customization of the LIMS systems assured that each sample was fully back trackable to meet CLIA regulations.

Legal and regulations

CLIA and MA clinical laboratory license

Before the pandemic, BU had held a long term CLIA license and corresponding Massachusetts Clinical Laboratory license for a high-complexity laboratory on the Charles River Campus. This small laboratory had been performing a genetic diagnostic test for a rare inborn error of metabolism called hereditary fructose intolerance [23]. Rather than applying for new CLIA and MA clinical laboratory licenses for the new COVID-19 laboratory, BU changed the location of its existing high-complexity laboratory’s licenses to the new on-campus COVID-19 laboratory. The construction of the CTL included a dedicated room for the continuation of diagnostic testing inside the new laboratory. The co-location of the old laboratory and the new laboratory allowed BU to use the existing CLIA and MA clinical laboratory licenses to perform SARS-CoV-2 testing. The new laboratory was successfully inspected by MA Department of Public Health in November 2020. The existence of this license and the long-standing relationship with the Massachusetts Department of Public Health greatly reduced the amount of paperwork required to move forward with test development and validation and allowed us to perform SARS-CoV-2 testing as soon as we completed validation testing without waiting for a MA Department of Public Health inspection. In addition, as the initial set up was nearing completion, BU hired a clinical laboratory supervisor with over 30 years of experience running CLIA laboratories.
FDA emergency use authorization

In the spring and summer of 2020, the FDA was reviewing and granting EUA status to laboratory developed tests (LDTs) like ours. We consulted with the FDA extensively and followed the template EUA for molecular LDTs [24] during our validation testing. We submitted a pre-EUA document to the FDA on June 19, 2020. This submission put us in the queue for full review. We received previously tested discarded samples from collaborators at the Boston Medical Center, LabCorp Inc., Genova Diagnostics, and the Massachusetts Department of Public Health. Results of our successful validation experiments were compiled and submitted as a supplement to the pre-EUA on July 27, 2020. FDA regulations allow CLIA laboratories to run tests and deliver results once validation data is submitted and before the EUA is approved.

On August 19, 2020, the Department of Health and Human Services (HHS) under the Trump administration announced that the FDA may not require premarket review for LDTs, including EUA submissions, absent a notice-and-comment rulemaking process. HHS noted that laboratories may voluntarily submit an EUA request for LDTs if it desired to be eligible for coverage under the Public Readiness and Emergency Preparedness (PREP) Act, which provides certain liability protections for covered persons administering covered medical countermeasures. In response to the HHS announcement, the FDA in October 2020 announced that it would “decline[e]” to review EUA requests for LDTs at this time,” including new EUA submissions and those already in the process of being reviewed. We continued (and continue) to maintain compliance with the FDA EUA requirements for our test, and HHS under the new Biden administration is still determining whether pending applications will be reviewed. CLIA requirements apply to clinical laboratories using LDTs, irrespective of a test’s EUA or approval status, and we continue to comply with all CLIA requirements.

Results and discussion

Limit of detection for SARS-CoV-2 plasmid

We documented the limit of detection (LoD) of the BU SARS-CoV-2 Test. A preliminary LoD study using IDT SARS-CoV-2 Plasmid Positive Control material spiked into the qPCR reaction was performed to assess the LoD with technical triplicates. The results showed a preliminary LoD of 10 copies per microliter (Table 1).

| Concentration | Result |
|---------------|--------|
| 1 × 10^8 copies/μl | Positive |
| 1 × 10^9 copies/μl | Positive |
| 1 × 10^5 copies/μl | Positive |
| 1 × 10^2 copies/μl | Positive |
| 1 × 10^1 copies/μl | Positive |
| 1 copies/μl | Negative |

Table 1: BU SARS-CoV-2 Test Preliminary LoD Study using IDT SARS-CoV-2 Plasmid Positive Control material. Preliminary LoD 10 copies per microliter.

Next, a known positive clinical specimen determined by an EUA-authorized test was used to generate dilutions in clinical matrix for LoD determination. Respiratory swab matrix solution from swab specimens collected from SARS-CoV-2 negative individuals was used as a diluent. We tested a 2-fold dilution series of three extraction replicates per concentration. The lowest concentration that gave positive results 100% of the time, 10.6 copies/μl, was defined as the preliminary LoD (Table 2).

Table 2: BU SARS-CoV-2 Test LoD Study using Pooled Positive Residual Patient Samples. LoD established at 10.6 copies per microliter.

| Concentration | Result |
|---------------|--------|
| 85 copies/μl | Positive |
| 42.5 copies/μl | Positive |
| 21.3 copies/μl | Positive |
| 10.6 copies/μl | Positive |
| 5.3 copies/μl | Negative |
| 2.7 copies/μl | Negative |

The BU CTL multiplexed assay has a LoD similar to the published CDC panel study’s LoD at 5 copies/μl [19]. Our primer and probe panel does not include the N3 target; a third primer set was no longer required by the CDC.

To comply with the FDA EUA regulations, assay validation checks against samples tested by another lab must achieve better than 95% sensitivity and specificity. If validation results do not meet this standard, new test results cannot be delivered to individuals until validation is met.

The clinical test results delivered to individuals are positive, negative, or invalid. The total viral load is not quantified by a standard curve for the clinical tests, nor is any quantitative data delivered.

Annual maintenance and assay validation

The continued maintenance of laboratory equipment and workflow validation is critical to the continued success of the BU CTL. Preventative maintenance by the manufacturers is performed twice per year on all the Microlab STAR and QuantStudio 7 Flex instruments to ensure they are functioning as expected.

The entire laboratory process is validated twice per year with a Proficiency Testing kit 385-21 SARS-CoV-2 (molecular) from the American Proficiency Institute. Each kit includes blinded samples; one positive and one negative for COVID-19.

Modifying existing testing for pooled sample testing

The development and distribution of vaccines in the US has resulted in a decrease in COVID-19 cases and deaths, which leads to the feasibility of implementing pooled sample testing [25,26]. The BU CTL planned and implemented pooled testing for the university. In a 1-month period during the Summer of 2021, the workflow for individual sample testing was modified by implementing algorithmic changes in the script responsible for sample data handling and analysis. In addition, the changes were implemented with updates to the Accession and Inactivation steps to pool 5 individual samples prior to the automation steps. Pooling has allowed for an increase in sample throughput while reducing the total reagent and consumable use. Pooling increased testing capabilities to 9,000 tests per day compared to the initial maximum of 6,200 test per day for individual testing. In addition to the notable increase in testing capacity, the average cost decreased to roughly $4.00 per test.
SARS-CoV-2 research emerging from the BU CTL and the research community

The robust high-throughput automated system in combination with on campus contact tracing enabled the BU research community to have access to data-rich deidentified information during the pandemic [7]. As an example, a multi-university effort that included BU discovered and determined that ampiclon residue contamination caused false positive PCR results in researchers working with amplified SARS-CoV-2 materials [27]. The large complete dataset enabled a large study on cycle threshold values correlated symptoms with SARS-CoV-2 positive and negative tests [28]. The rapid emergence of the omicron variant was documented at BU and on other local university campuses [29]. A study on matched anterior nares swabs tested with both RT-PCR and Abbott BinaxNOW™ (Abbott Laboratories, Chicago, IL) was critical during the omicron surge as the demand for rapid diagnostic tests increased [28]. Data from the BU CTL, contact tracing, and sequencing data provided insight on vaccine efficacy [30], transmission of SARS-CoV-2 in classrooms [31], post-quarantine transmission and quarantine length [32], and isolation release after infection [33].

Considerations and future research opportunities

BU has successfully implemented a screening testing program for the 2020-2021 academic school year with the plan to continue to allow for students, staff, and faculty to safely return to campus. The rapid scale-up of the BU CTL has provided critical insights on materials, space, legal, and personnel required to effectively build an automated high-throughput system in a short period of time leading to a model that can be referenced for future disease outbreaks and pandemics. With over 1 million tests completed this academic year, the university has the unique opportunity to conduct research to contribute to the global SARS-CoV-2 knowledgebase. The university has a controlled data diverse set of de-identified samples that could provide further insight into SARS-CoV-2 and its impacts on public health.

Author contributions

L.L., D.M., J.R., D.F., L.O., R.C., S.M.D.O., and A.F. built and tested the laboratory and biological assays. S.C., D.C., S.H., C.K., T.L.M., E.M., M.M., and T.S. contributed to the database and software support for the BU CTL. A.B., S.P.B., S.C., D.C., L.D., K.G., D.H.H., L.H., C.L., D.L., K.L., C.M., C.M., R.P., L.R., J.R., D.R.T., A.Z., R.A.B., G.W., D.D., and C.M.K. contributed to the development of the BU CTL, BU Healthway, and Learn from Anywhere. L.L. and C.M.K. wrote the manuscript. All authors reviewed and approved the final manuscript.

Declaration of interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

Figures were drawn by the Authors of this paper. Photos are taken by authors of the paper. Images are stock from ThermoFisher, Hamilton, and Boston University. The authors of the paper would like to thank our collaborators from across the country including the Broad Institute, University of California Berkeley, and University of California San Diego. Thank you to Sandra Smole and Massachusetts Department of Public Health for their continued support. Thank you to Marcia Eisenberg and LabCorp, Inc. for technical assistance and advice. Thank you to Amy Peace Brewer and Genova Diagnostics for technical assistance and advice. Thank you to the support of Rajen Kilachand and the Rajen Kilachand Center for Integrated Life Sciences & Engineering for the support to develop the BU CTL. Thank you to the technicians, technologists, and Lab Managers of the BU CTL. The authors would like to thank the BU Facilities Management and Operations.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.slas.2022.06.003.

References

[1] Astuti I, Yrasafi. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response. Diabetes Metab Syndr 2020;14:407.
[2] Huang C, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet North Am Ed 2020;395:497–506.
[3] Pneumonia of unknown cause – China 2022. https://www.who.int/emergencies/disease-outbreak-news/item/2020-DION22.
[4] Holdblue ML, et al. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med 2020;382:929–36.
[5] Cicconi D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomedica 2020;91:157–60.
[6] Organization, W. II.Laboratory testing strategy recommendations for COVID-19- interim guidance, 21 March 2020. p. 6 (2020).
[7] Hamer DH, et al. Assessment of a COVID-19 Control Plan on an Urban University Campus During a Second Wave of the Pandemic. JAMA Netw Open 2021;4:e2116425.
[8] Amen AM, et al. Blueprint for a pop-up SARS-CoV-2 testing lab. Nat Biotechnol 2020;38:791–7.
[9] Aitken J, et al. Scalable and robust SARS-CoV-2 testing in an academic center. Nat Biotechnol 2020;38:927–31.
[10] Vanuytsel K, et al. Rapid Implementation of a SARS-CoV-2 Diagnostic Quantitative Real-Time PCR Test with Emergency Use Authorization at a Large Academic Safety Net Hospital. Med N Y N Y 2020:1:152.
[11] BMC-CReM/BMC-CReM COVID-19 Test. Two-Step Singleplex and One-Step Singleplex EUA Summary 2022. https://www.fda.gov/media/140007/download.
[12] Giadone RM, et al. qRT-PCR Platforms for Diagnosing and Reporting SARS-CoV-2 Infection in Human Samples. STAR Protoc 2020;2:100102.
[13] Commission, O. of. the. Emergency Use Authorization. FDA https://www.fda.gov/emergency-preparedness-and-response/cmem-legal-regulatory-and-policy-framework/emergency-use-authorization (2021).
[14] Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency (Revised) – Guidance for Developers and Food and Drug Administration Staff 2022.
[15] Code of Federal Regulations 42 CFR §2022.493.
[16] CLIA Regulations and Federal Register Documents. CMS 2022. https://www.cms.gov/Regulations-and-Guidance/Legislation/CLIA/CLIARegulationsandFederalRegister/Documents.
[17] Chowdhury P, Fauz SK, Kaisar S, Mokhtar MD. COVID-19 pandemic related supply chain studies: A systematic review. Transp Res Part E Logist Transp Rev 2021;148:102271.
[18] CDC. Labs. Centers for Disease Control and Prevention 2020. https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-sequences.html.
[19] Liu X, et al. US CDC real-time reverse transcription PCR panel for detection of severe acute respiratory syndrome Coronavirus 2. Emerg Infect Dis 2020;26:1654–65.
[20] FDA. FoodPath COVID-19 Combo Kit - Letter of Authorization 2020.
[21] CDCOverview of Testing for SARS-CoV-2 (Covid-19). Centers for Disease Control and Prevention 2020. https://www.cdc.gov/coronavirus/2019-ncov/laboratory/cdc-testing-overview.html.
[22] User Guide: MagMAX Viral/Pathogen II Nucleic Acid Isolation Kit. 2022 https://www.thermofisher.com/document/connect/document-connect.html?url= http%3A%2F%2Fassets.thermofisher.com%2FTFS-Assets%2FS0-%2Fmanuals-%2FMANO024756_MVPNL_RUOG_.pdf&title=VXNlc1BiBldWlkZTogTWFnTUFYIFZpcmFsb1BhdGlvZ2VuIEJ1EjEyI2l2aW5gQWxQNome29c2VhYXRpb24gN20=. 2022.
[23] Coffee EM, Tolon DR. Mutations in the Promoter Region of the Aldolase B Gene that cause Hereditary Fructose Intolerance. J Inherit Metab Dis 2010;33:715–25.
[24] FDAIn Vitro Diagnostics EUAs. FDA Molecular Diagnostic Template for Laboratories 2022. https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas.
[25] Pooled Sample Testing and Screening Testing for COVID-19. FDA 2022. https://www.fda.gov/medical-devices/coronavirus-covid-19-medical-devices/pooled-sample-testing-and-screening-testing-covid-19.
[26] Christie A, et al. Decreases in COVID-19 Cases, Emergency Department Visits, Hospital Admissions, and Deaths Among Older Adults Following the Introduction of COVID-19 Vaccine — United States, September 6, 2020–May 1, 2021. Morb Mortal Wky Rep 2021;70:858.
[27] Davidi D, et al. Ampliclon residues in research laboratories masquerade as COVID-19 in surveillance tests. Cell Rep Methods 2021;1:100005.
[28] Landaverde L, et al. Comparison of BinaxNOWTM and SARS-CoV-2 qRT-PCR detection of the Omicron Variant from Matched Anterior Nares Swabs 2022;2022.01.31.22220306. 2021.
[29] Petros BA, et al. Early introduction and rise of the Omicron SARS-CoV-2 variant in highly vaccinated university populations 2022;2022.01.27.222269787. doi:10.1101/2022.01.27.222269787.
[30] Landsberg HE, et al. Efficacy of Pfizer-BioNTech in SARS-CoV-2 Delta cluster. Int J Infect Dis 2022;114:62–4.

[31] Kuhfeldt K, et al. Minimal SARS-CoV-2 classroom transmission at a large urban university experiencing repeated into campus introduction 2022 2022.03.16.22271983. doi:10.1101/2022.03.16.22271983.

[32] Liu AB, et al. Association of COVID-19 Quarantine Duration and Postquarantine Transmission Risk in 4 University Cohorts. JAMA Netw Open 2022;5:e220088.

[33] Bouton TC, et al. Viral dynamics of Omicron and Delta SARS-CoV-2 variants with implications for timing of release from isolation: a longitudinal cohort study. medRxiv 2022 2022.04.04.22273429. doi:10.1101/2022.04.04.22273429.